Beyond the Dose: Establishing Optimal Mycophenolate Therapeutic Drug Monitoring Targets for Nephrotic Syndrome in Children (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0824; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Methods We performed a retrospective analysis of children with nephrotic syndrome (aged 1–18 years) treated with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium, with AUC measured between 2019-2025...Most children (87%) received MPA after rituximab...Conclusion Our findings suggest an initial target MPA-AUC 0-12h between 40-60mg*h/L provided an optimal balance between relapse prevention and adverse effects. Further increases of MPA-AUC 0-12h above 60mg*h/L may provide further relapse risk reduction, but should be carefully weighed against neutropenia risk."
Clinical • Glomerulonephritis • Hematological Disorders • Nephrology • Neutropenia • Renal Disease
|
|
Magdalena Riedl Khursigara; Cal Robinson; Erin Chung; Winnie Seto; Diana Hamdan; Junhee Hong; Valentina Bruno; Nowrin F. Aman; Tonny Hue Minh Banh; Josefina A. Brooke; Vaneet Dhillon; Mackenzie Alexander Garner; Christoph Licht; Ashlene Maree McKay; Damien Gerard Noone; Rachel Jane Pearl; Seetha Radhakrishnan; Keisha Rasool; Nithiakishna Selvathesan; Kristen Vanos Hosick; Jovanka Vasilevska-Ristovska; Rulan S. Parekh; James Anthony Tjon; Chia Wei Teoh
|